Literature DB >> 16366600

N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.

F Ivy Carroll1, Sachin Chaudhari, James B Thomas, S Wayne Mascarella, Kenneth M Gigstad, Jeffrey Deschamps, Hernán A Navarro.   

Abstract

N-Substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines (6a-g) were designed and synthesized as conformationally constrained analogues of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (4) class of opioid receptor pure antagonists. The methyloctahydroisoquinolines 6a-g can exist in conformations where the 3-hydroxyphenyl substituent is either axial or equatorial, similar to the (3-hydroxyphenyl)piperidines 4. The 3-hydroxyphenyl equatorial conformation is responsible for the antagonist activity observed in the (3-hydroxyphenyl)piperidine antagonists. Single-crystal X-ray analysis of 6a shows that the 3-hydroxyphenyl equatorial conformation is favored in the solid state. Molecular modeling studies also suggest that the equatorial conformation has lower potential energy relative to that of the axial conformation. Evaluation of 6a-g in the [(35)S]GTP-gamma-S in vitro functional assay showed that they were opioid receptor pure antagonists. N-[4a-(3-Hydroxyphenyl)-8a-methyl-2-(3-phenylpropyl)octahydroisoquinoline-6-yl]-3-(piperidin-1-yl)propionamide (6d) with a K(e) of 0.27 nM at the kappa opioid receptor with 154- and 46-fold selectivity relative to those of the micro and delta receptors, respectively, possessed the best combination of kappa potency and selectivity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16366600      PMCID: PMC2585695          DOI: 10.1021/jm058261c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  25 in total

1.  5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist.

Authors:  R M Jones; P S Portoghese
Journal:  Eur J Pharmacol       Date:  2000-05-12       Impact factor: 4.432

2.  Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.

Authors:  J B Thomas; R N Atkinson; R B Rothman; S E Fix; S W Mascarella; N A Vinson; H Xu; C M Dersch; Y Lu; B E Cantrell; D M Zimmerman; F I Carroll
Journal:  J Med Chem       Date:  2001-08-16       Impact factor: 7.446

Review 3.  Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.

Authors:  W K Schmidt
Journal:  Am J Surg       Date:  2001-11       Impact factor: 2.565

4.  Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.

Authors:  R M Jones; S A Hjorth; T W Schwartz; P S Portoghese
Journal:  J Med Chem       Date:  1998-12-03       Impact factor: 7.446

5.  Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists.

Authors:  J B Thomas; S W Mascarella; R B Rothman; J S Partilla; H Xu; K B McCullough; C M Dersch; B E Cantrell; D M Zimmerman; F I Carroll
Journal:  J Med Chem       Date:  1998-05-21       Impact factor: 7.446

6.  Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.

Authors:  W C Stevens; R M Jones; G Subramanian; T G Metzger; D M Ferguson; P S Portoghese
Journal:  J Med Chem       Date:  2000-07-13       Impact factor: 7.446

7.  Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders.

Authors:  D M Zimmerman; J S Gidda; B E Cantrell; D D Schoepp; B G Johnson; J D Leander
Journal:  J Med Chem       Date:  1994-07-22       Impact factor: 7.446

8.  Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.

Authors:  J B Thomas; M J Fall; J B Cooper; R B Rothman; S W Mascarella; H Xu; J S Partilla; C M Dersch; K B McCullough; B E Cantrell; D M Zimmerman; F I Carroll
Journal:  J Med Chem       Date:  1998-12-17       Impact factor: 7.446

9.  3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.

Authors:  C H Mitch; J D Leander; L G Mendelsohn; W N Shaw; D T Wong; B E Cantrell; B G Johnson; J K Reel; J D Snoddy; A E Takemori
Journal:  J Med Chem       Date:  1993-10-01       Impact factor: 7.446

10.  N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.

Authors:  J B Thomas; X Zheng; S W Mascarella; R B Rothman; C M Dersch; J S Partilla; J L Flippen-Anderson; C F George; B E Cantrell; D M Zimmerman; F I Carroll
Journal:  J Med Chem       Date:  1998-10-08       Impact factor: 7.446

View more
  7 in total

1.  Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.

Authors:  D Matthew Walentiny; Robert E Vann; Jonathan A Warner; Lindsey S King; Herbert H Seltzman; Hernán A Navarro; Charles E Twine; Brian F Thomas; Anne F Gilliam; Brian P Gilmour; F Ivy Carroll; Jenny L Wiley
Journal:  Psychopharmacology (Berl)       Date:  2010-03-31       Impact factor: 4.530

2.  Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity.

Authors:  Scott P Runyon; Lawrence E Brieaddy; S Wayne Mascarella; James B Thomas; Hernán A Navarro; James L Howard; Gerald T Pollard; F Ivy Carroll
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

3.  Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).

Authors:  Juan Pablo Cueva; Tingwei Bill Cai; S Wayne Mascarella; James B Thomas; Hernán A Navarro; F Ivy Carroll
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

4.  Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.

Authors:  Cecilea C Clayton; Michael R Bruchas; Michael L Lee; Charles Chavkin
Journal:  Mol Pharmacol       Date:  2009-12-03       Impact factor: 4.436

5.  Design, Synthesis, and Biological Evaluation of Structurally Rigid Analogues of 4-(3-Hydroxyphenyl)piperidine Opioid Receptor Antagonists.

Authors:  Scott P Runyon; Chad M Kormos; Moses G Gichinga; S Wayne Mascarella; Hernán A Navarro; Jeffrey R Deschamps; Gregory H Imler; F Ivy Carroll
Journal:  J Org Chem       Date:  2016-08-02       Impact factor: 4.354

6.  Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of replacement of the 3-hydroxyphenyl group with pyridine or thiophene bioisosteres.

Authors:  Chad M Kormos; Moses G Gichinga; Scott P Runyon; James B Thomas; S Wayne Mascarella; Ann M Decker; Hernán A Navarro; F Ivy Carroll
Journal:  Bioorg Med Chem       Date:  2016-06-15       Impact factor: 3.641

7.  4β-Methyl-5-(3-hydroxyphenyl)morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl)morphan pure antagonist.

Authors:  F Ivy Carroll; Moses G Gichinga; John D Williams; Eyal Vardy; Bryan L Roth; S Wayne Mascarella; James B Thomas; Hernán A Navarro
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.